1. Home
  2. JAGX vs XBIO Comparison

JAGX vs XBIO Comparison

Compare JAGX & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JAGX
  • XBIO
  • Stock Information
  • Founded
  • JAGX 2013
  • XBIO N/A
  • Country
  • JAGX United States
  • XBIO United States
  • Employees
  • JAGX N/A
  • XBIO N/A
  • Industry
  • JAGX Biotechnology: Pharmaceutical Preparations
  • XBIO Biotechnology: Pharmaceutical Preparations
  • Sector
  • JAGX Health Care
  • XBIO Health Care
  • Exchange
  • JAGX Nasdaq
  • XBIO Nasdaq
  • Market Cap
  • JAGX 3.9M
  • XBIO 4.4M
  • IPO Year
  • JAGX N/A
  • XBIO N/A
  • Fundamental
  • Price
  • JAGX $1.97
  • XBIO $3.47
  • Analyst Decision
  • JAGX Strong Buy
  • XBIO Hold
  • Analyst Count
  • JAGX 1
  • XBIO 1
  • Target Price
  • JAGX $60.00
  • XBIO N/A
  • AVG Volume (30 Days)
  • JAGX 140.0K
  • XBIO 14.7K
  • Earning Date
  • JAGX 11-12-2025
  • XBIO 11-11-2025
  • Dividend Yield
  • JAGX N/A
  • XBIO N/A
  • EPS Growth
  • JAGX N/A
  • XBIO N/A
  • EPS
  • JAGX N/A
  • XBIO N/A
  • Revenue
  • JAGX $11,810,000.00
  • XBIO $2,446,221.00
  • Revenue This Year
  • JAGX $22.41
  • XBIO $1.99
  • Revenue Next Year
  • JAGX $30.00
  • XBIO $20.00
  • P/E Ratio
  • JAGX N/A
  • XBIO N/A
  • Revenue Growth
  • JAGX 15.96
  • XBIO N/A
  • 52 Week Low
  • JAGX $1.57
  • XBIO $2.20
  • 52 Week High
  • JAGX $35.25
  • XBIO $5.27
  • Technical
  • Relative Strength Index (RSI)
  • JAGX 49.42
  • XBIO 62.87
  • Support Level
  • JAGX $1.88
  • XBIO $2.97
  • Resistance Level
  • JAGX $2.16
  • XBIO $3.70
  • Average True Range (ATR)
  • JAGX 0.12
  • XBIO 0.21
  • MACD
  • JAGX 0.06
  • XBIO 0.08
  • Stochastic Oscillator
  • JAGX 67.80
  • XBIO 75.49

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.

About XBIO Xenetic Biosciences Inc.

Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.

Share on Social Networks: